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ABSTRACT
Introduction. There is no single, commonly accepted, standard definition of secondary progressive multiple sclerosis (SPMS), 
an absence that poses a challenge for clinicians.
State of the art. SPMS is characterised by inflammation, neurodegeneration and disease progression with the presence or absen-
ce of relapses. No biochemical or radiological biomarkers are currently available to indicate the precise secondary progressive co-
urse in individual patients. The retrospective approach to identifying SPMS patients raises many difficulties, especially in terms of 
determining the time point of progression. Currently, the most precise diagnosis of SPMS is based on the definition proposed by 
Lorscheider et al., where SPMS is defined as a disability progression by 1 step on the Expanded Disability Status Scale (EDSS) in pa-
tients with EDSS ≤ 5.5 or of 0.5 EDSS steps in patients with EDSS ≥ 6 in the absence of a relapse, a minimum EDSS score of 4 and pyra-
midal functional system (FS) score of 2, and confirmed progression over ≥ 3 months, including confirmation within the leading FS. 
Clinical implications. The need to establish criteria for the diagnosis of SPMS is currently of crucial importance due to 
emerging treatment opportunities including siponimod, a sphingosine 1-phosphate (S1P) receptor modulator se-
lective for S1P1 and S1P5 receptors. It is reasonable to introduce drugs at the earliest possible stage of lesion progres-
sion to reduce inflammation and to protect the central nervous system (CNS) against irreversible neurodegeneration. 
Future directions. Further studies with prospective, multicentre and long term follow-up design are needed to provide better 
insights into SP course in MS patients. This should be supported by radiological, biochemical and pathological evaluations to 
help establish reliable and sensitive biomarkers to guide clinical practice.
Key words: secondary progressive multiple sclerosis, disease progression, SPMS definition, SPMS neuropathology, SPMS 
treatment
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Introduction 
Today, secondary progressive multiple sclerosis (SPMS) is 
under extensive analysis. It is characterised by inflammation, 
neurodegeneration and disease progression with the presence 
or absence of relapses. Compared to patients with relapsing 
remitting multiple sclerosis (RRMS), patients with SPMS are 
usually older, have a higher degree of disability, a lower number 
of Gd+ lesions on T1-weighted images, and a larger volume 
of lesions on T2-weighted images on MRI [1].
However, the standardised definition of SPMS is yet to be 
established. There are currently no clear imaging, immuno-
logical, clinical or pathological criteria to determine the point 
at which RRMS converts to SPMS [2]. 
Establishing a uniform definition of SPMS would improve 
the comparability of clinical trials and observational studies 
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and could offer better treatment results (faster patient enroll-
ment for modern treatment modalities). 
SPMS is difficult to diagnose retrospectively [2]. It is 
currently diagnosed based on a gradual worsening of the 
patient’s condition after the initial relapsing course with or 
without acute exacerbations during the disease progression. 
Conversion from RRMS to SPMS is observed 20 years after 
the diagnosis in 30–60% of cases (Fig. 1) [3].
It is necessary to carefully study the pathological mecha-
nisms of disease progression to better understand the diagnos-
tic and therapeutic targets in SPMS. Primary demyelination 
with partial axonal survival is the most characteristic process 
of RRMS, whereas brain atrophy is the main source of irre-
versible disability in progressive forms of multiple sclerosis 
(MS) [4]. Axonal degeneration begins early in active MS [5, 
6]. However, initially, this does not result in disability. This is 
due to the fact that the human brain has an amazing ability 
to compensate [7]. Degeneration of demyelinated axons has 
been postulated as the leading feature of SPMS and a major 
cause of disability [4]. 
It seems that neuropathology could contribute to under-
standing the pathomechanism of SPMS. ‘Smouldering’ plaques 
within the white matter containing iron deposits are typical of 
SPMS, but these plaques are not found in RRMS. Importantly, 
iron plays a role in generating oxidative stress and neurode-
generation in MS [8]. These changes pose major diagnostic 
and therapeutic challenges and require further careful analysis.
Ruano et al. found that progressive forms of MS predispose 
to the development of cognitive disorders [9, 10]. Furthermore, 
it seemed that the thickness of cortical areas assessed in SPMS 
may be important in the impairment of attention in SPMS 
patients [11]. Assessment of both cognitive functions and 
fatigue has a great impact on the quality of life [12]. Kizlaitienė 
et al. proved in their study that a composite marker of cog-
nitive dysfunction with brain atrophy is a good differentiator 
between RRMS and SPMS [13]. Carotenuto et al. conducted 
an interesting study based on the relationship between cog-
nitive impairment and olfactory impairment [14]. Patients 
with SPMS have more severe olfactory disorders, language 
and visuospatial deficits than do patients with RRMS [14, 15]. 
This information should be considered when searching for 
new drugs. Cognitive processes in SPMS patients may be im-
paired with disease duration and age. New drugs should have 
a significantly positive effect on improving daily functioning 
of patients. Siponimod is the latest recommended active SPMS 
treatment [16].
Correlation between neuroimaging and MS 
progression 
Based on MRI findings, damage may be greater than 
predicted. Furthermore, disease progression is related to 
the failure of remyelination [17]. Focal plaques in the initial 
course of RRMS are only part of the processes, whereas lesions 
accumulate and become significant with disease progression 
[4]. Other neuropathological changes include spinal cord 
lesions, meningitis, grey matter lesions and diffuse damage 
to the normal-appearing white matter (NAWM) [18, 19]. 
Additionally, cortical demyelination [18, 19] and diffuse pa-
thology (axonal injury, microglial activation, atrophy) were 
found in normal-appearing grey and white matter. However, 
they were not detected during standard follow-up tests [20]. 
Therefore, new methods to confirm disease progression in 
imaging studies should be sought to visualise the lesions that 
are not detected on standard MRI. 
Grey matter atrophy could be a marker of disease pro-
gression. Furthermore, it could correlate with the degree 
of neurodegeneration [21]. Cerebral cortex thickness has 
been shown to correlate better with the degree of disability, 
including cognitive decline, compared to focal white matter 
lesions [22].
Degeneration of demyelinated neurons results in irre-
versible disability. The process is typical of SPMS [4, 23–25]. 
Therefore, grey matter atrophy may become a potential marker 
of SPMS. Various semi-automated longitudinal methods for 
measuring grey matter atrophy have been developed. They 
could be used in everyday practice in the future [26, 27]. 
Moreover, total brain atrophy and spinal cord atrophy also 
correlate with axonal loss and may be a sensitive biomarker 
of disease progression [6, 21, 28–30].
The retinal nerve fibre layer (RNFL) and ganglion cell layer 
(GCL) could be evaluated by optical coherence tomography 
(OCT). GCL correlates with the Expanded Disability Status 
Scale (EDSS). However, the RNFL is also correlated with brain 
atrophy and overall disability [31–33]. Thinning of the RNFL 
has been observed during SPMS despite the absence of relaps-
es, and could represent the degree of brain neurodegeneration 
[34]. New imaging methods (e.g. diffusion tensor imaging and 
magnetisation transfer ratio MRI) could be used in future to 
assess disease progression [21].
Neuropathology — the key to understanding 
SPMS
MS is a chronic autoimmune disease of the central nervous 
system (CNS). According to the generally accepted theory, 
predominantly white matter myelin is the primary target of the 
Figure 1. Progressive clinical worsening between relapses indicates 
upcoming SPMS
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autoimmune attack. It is assumed that the processes of neu-
rodegeneration are a secondary phenomenon. Nevertheless, 




T lymphocytes are mainly represented by a subpopulation 
of CD3+, CD8+ cells and CD4+ helper cells. CD8+ cells are cyto-
toxic (granzyme B expression) or have the features of memory 
lymphocytes. The importance of CD4+ cells increased after the 
discovery of the Th17 subtype derived from the population of 
CD4+ lymphocytes mediated by transforming growth factor 
beta (TGF-b) and interleukin 6 (IL-6) [37]. Th17 lymphocyte 
activity is thought to be particularly high in the early stages 
of the immune attack (active plaque formation). These cells 
contribute to an increase in the permeability of the blood-brain 
barrier (BBB) [38]. CD4+ lymphocytes are responsible for the 
recruitment of macrophages, i.e. antigen-presenting cells, and 
thus participate in the formation of new demyelination. CD8+ 
lymphocytes tend to be in close contact with oligodendroglial 
cells and axons [39].
The above cells accumulate around the vessels, especially 
in demyelinating foci (plaques), forming dense infiltrates. They 
also infiltrate the pia mater, although their percentage there is 
lower than that of B lymphocytes. 
B lymphocytes 
B lymphocytes and the resulting plasma cells occur in the 
CNS during the RRMS much less frequently than T lympho-
cytes. A special role is assigned to CD20 and CD19. As in the 
case of T cells, they are also part of perivascular infiltrates. 
However, they are mostly present in the pia mater, forming 
structures with features resembling tertiary lymphoid struc-
tures with germinal centres [40]. The structures are mainly 
formed by large B-cells [41]. 
Thus, a vicious circle is formed in a particularly acute pe-
riod of inflammation. Plasma cells produce immunoglobulins, 
especially IgG1 and IgG3 isotypes, and less frequently IgA and 
IgM. Oligoclonal IgA bands in the cerebrospinal fluid (CSF) 
are a marker of humoral immunity, whereas the presence of 
IgM is reported in a more aggressive course directed against 
myelin lipids [42]. B lymphocytes promote inflammation 
by direct and indirect effects on T cells. They secrete more 
tumour necrosis factor alpha (TNF-α) in the presence of 
pro-inflammatory interferon gamma (IFN-γ) produced by T 
lymphocytes. The destructive characteristics of B lymphocytes 
also results from overexpression of nitric oxide and hyper-
reactive oxygen by these cells. Some authors have reported 
the ‘two-faced’ character of B lymphocytes in the pathogenesis 
of MS. On the one hand, these cells have a proinflammatory 
effect. On the other hand, they have an immunomodulatory 
effect by contact with T lymphocytes which secrete inhibitory 
cytokines, i.e. IL-10, TGF-β [43]. 
Microglia/macrophages
Long-term studies on the participation of microglia/
macrophages in the pathogenesis of MS have confirmed the 
proinflammatory roles of these cells. They occur already in 
the early stages of the disease, initially particularly in ac-
tive plaques in white and grey matter, especially in subpial 
plaques. Proliferation of microglia/macrophages also occurs 
in SPMS, not only in plaques but also in distant locations 
including NAWM. Their proinflammatory activity increases 
with the duration of the disease. These cells cause damage 
to the nervous tissue by antigen presentation via the major 
histocompatibility complex (MHC), releasing reactive oxy-
gen and nitrogen, secreting proinflammatory cytokines and 
participating in phagocytosis. Demyelination, axonal dam-
age, and neuronal degeneration are associated with a marked 
microglial activity [42, 44, 45]. 
Demyelination/remyelination
Myelin is the primary target of an immune attack. Firstly, 
degradation of myelin oligodendrocyte glycoprotein (MOG) 
occurs within two days. MOG is characterised by a low mo-
lecular weight and is expressed on the outer surface of the my-
elin sheath. Degradation of proteins with a higher molecular 
weight, especially myelin basic protein (MBP), occurs within 
six days. Myelin-associated glycoprotein (MAG), which is 
a structural protein and a component of the oligodendrocyte 
membrane, is also the target of attack [46]. Additionally, 
oxidative stress results in direct damage to oligodendrocytes 
with the loss of MAG and apoptosis. The above reactions are 
triggered and mediated by macrophages and active microglia 
that are abundant in inflammatory foci [47]. 
Blood-brain barrier
Autoreactive lymphocytes, which are primed in the periph-
ery, infiltrate the CNS to trigger an autoimmune reaction, which 
shows the basic role of the BBB in the pathogenesis of MS [48]. 
Crossing the BBB occurs through the interactions between 
lymphocyte integrins and adhesion molecules on the surface 
of endothelial cells. In acute active plaques, the BBB damage is 
centrally located in the most active area, whereas in the case of 
chronic active plaques the BBB damage is related to the rim [49].
Neurodegeneration
Degenerative changes in the CNS tissue are an integral 
part of the pathogenic picture of MS. The theory of primary 
myelin damage with the secondary activation of the processes 
resulting in neurodegeneration is commonly accepted [23]. 
Changes in demyelinated axons are the key point in the ini-
tiation of neurodegeneration. Severe Wallerian degeneration 
is mostly related to acute plaques. Less commonly, it may be 
also detected in diffusely abnormal white matter (DAWM) or 
even in NAWM [50]. It is mainly responsible for the loss of 
the white matter, considering the fact that as much as 45% of 
white matter mass is composed of axons and also responsible 
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for the loss of neurons in the cortex, and thus contributing 
to its atrophy [51]. 
Neuropathological changes and their 
location  
Brain white matter 
MS plaques 
a) Acute plaques are characterised by extensive infiltration of 
CD68+ cells (macrophages / microglia). If macrophages are 
laden with myelin degradation products, particularly myelin 
basic protein (MBP), MOG, or MAG, the demyelinating 
lesion is acute. Slightly older ‘post-demyelinating’ plaques 
with numerous macrophages laden with non-specific lipid 
products do not show the presence of MAG or MOG (MAG-, 
MOG-). Both stages last 4-8 months. T and B cells are local-
ised perivascularly and diffusely throughout the lesion area. 
b) Chronic active plaques (so-called ‘smouldering’, mixed active/
inactive lesions). Lymphocytic and macrophage/microglial 
infiltrates involve the rim at the lesion border and decrease 
in intensity centrally. These plaques are characterised by a hy-
pocellular lesion centre. Demyelination is pronounced in the 
centre of the plaques. The stages of early demyelination and 
post-demyelination are found on the rim with the occurrence 
of remyelination. Axonal damage is more extensive than in 
acute plaques and hypertrophic astrocytes are also detected.
c) Chronic inactive (‘burn-out’) plaques. These lesions are 
sharply demarcated from the surroundings. Myelitis and 
myelin destruction decrease in intensity. However, only 
a small number of T cells and microglia/macrophages are 
still present within the lesion. In addition to demyelination, 
these lesions are almost completely depleted of oligo-
dendroglia and oligodendroglial progenitor cells, which 
hinders or even prevents remyelination. Axonal damage 
is evident, and axonal density is significantly reduced. 
However, scattered axonal swelling may indicate some 
ongoing neurodegeneration. Intense astrogliosis (particu-
larly fibrous) changes the plaque into a gliotic scar [52].
Diffusely abnormal white matter (DAWM)
This area surrounds the plaques and is characterised by 
poorly defined borders and T-cell and B-cell perivascular 
and interstitial inflammatory infiltrates. Additionally, diffuse 
myelin pallor and the local loss of myelin are typical features 
of DAWM. Axonal damage and thinning are observed. Mi-
croglial and astroglial proliferation is evident. DAWM shows 
a predilection for periventricular location.
Normal-appearing white matter (NAWM)
In addition to plaques and DAWM, macroscopic appear-
ance of the white matter shows no abnormalities. However, 
changes are found microscopically, particularly under higher 
magnification. BBB is damaged, myelin pallor, axonal damage, 
and local myelin and axonal loss are observed. Small diffuse 
inflammatory infiltrates are also present. Active microglial 
and astroglial proliferation is evident.
Brain grey matter
Grey matter damage occurs in the early stage of the disease 
and is a direct effect of inflammation, particularly in the pia 
mater. Neuronal loss in Wallerian degeneration is also present. 
Neuronal loss results in a massive loss of synapses. 
The nature of the plaques in the grey matter is similar to 
that in the white matter. Cortical plaques include subarach-
noid, purely cortical, and cortico-subcortical lesions. They 
contain a higher number of B cells from the pia mater. Plaques 
in the grey matter show a predilection for the involvement of 
the motor cortex, thalamus, hypothalamic region, caudate nu-
clei, CA1-CA3 sectors of the hippocampus and the spinal cord.
Spinal cord 
MS plaques   
Approximately 80-90% of patients with MS present with 
plaques in the spinal cord. Their nature and dynamics are simi-
lar to those located in the brain. Considering the spinal cord 
parameters, even single lesions are crucial in generating clinical 
symptoms. The number of plaques ranges from a few to many 
lesions. Most lesions reach more than 3 cm on axial images. They 
show a predilection for lateral and posterior columns compared 
to anterior columns. Considering the thickness of the spinal 
cord, no significant differences have been observed in terms of 
the occurrence of plaques at different heights of the spinal cord. 
Lesions involve the grey matter in about 20% of cases, and 
the white matter in more than 30%.  In 45% of cases, lesions 
involve both. It is still unknown why the plaques are sharply 
limited to the grey or white matter [53]. Active lesions are more 
prevalent in the acute phase of the disease, but also occur in 
the advanced stage of MS.
Neurodegeneration
Axonal loss is present and affects axons of any calibre 
throughout the length of the spinal cord [54]. The degree of 
axonal damage correlates with the degree of myelin damage, 
whereas axonal density correlates with the duration of the 
disease [55]. Extensive axonal lesions are seen in the DAWM 
of the spinal cord. The origin of axonal lesions in the spinal 
cord is probably complex and some of them develop in active 
plaques in the spinal cord. Axonal damage also occurs in the 
course of Wallerian degeneration as a result of the activity of 
plaques and DAWM lesions in the brain. 
Relapsing-remitting vs. secondary 
progressive multiple sclerosis — 
neuropathological aspects
Neuropathological changes in the CNS in RRMS and SPMS 
are basically similar and overlap [23]. However, the prevalence 
and severity of changes evolve with the duration of the disease.
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Inflammatory/proliferative activity
In RRMS, active inflammatory changes in the form of 
plaques are prevalent mostly in the white matter. Macrophages 
are laden with early myelin degradation products. In SPMS, 
the number of newly formed active plaques in the white matter 
is significantly lower. However, many acute plaques in RRMS 
are transformed into chronic active plaques whose percent-
age in SPMS steadily increases in relation to acute plaques 
[56]. Inflammatory activity, although significantly reduced, 
persists permanently. Macrophages with early myelin degrada-
tion products still occur at the rim of chronic active plaques. 
A significant microglial reaction and diffuse astroglial reaction 
are noted in the vicinity of the plaques in DAWM and even in 
NAWM. Small perivascular inflammatory infiltrates are found 
in many areas of NAWM. They are surrounded by a narrow 
rim of degraded myelin. Damage to the NAWM affects ap-
proximately 90% of cases.
Inflammatory infiltrates in the pia mater that resemble 
lymphoid follicles are more prevalent in SPMS compared 
to RRMS. Their severity increases with the duration of the 
disease, and reaches a peak in early SPMS. Such infiltrates 
increase the risk of a more aggressive course of the disease 
against the background of diffuse CNS damage.
Neurodegenerative activity
Diffuse neurodegeneration in the white and grey matter is 
typical of SPMS. Marked axonal damage, reduced presynaptic 
endings, and neuronal loss are found in the cortex. These 
phenomena are mainly associated with two mechanisms i.e. 
retrograde Wallerian degeneration involving the white matter, 
and inflammatory infiltrates in the pia mater. Extensive demy-
elination, profound axonal damage and loss, and above all pro-
found microglial and astroglial proliferation are predominant in 
the white matter. Astroglial proliferation is responsible for the 
formation of a dense fibrous scar, especially in previously active 
areas. The severity of scarring in advanced stages of MS can be 
so extensive that remyelination is not possible. The loss of grey 
and white matter of the brain and spinal cord is irreversible. 
The mechanisms of degeneration in SPMS are not fully 
understood. On the one hand, ongoing inflammation in SPMS 
is involved in degeneration. On the other hand, an increasing 
failure of remyelination in neural structures damaged during 
RRMS is also reported [23]. There is no doubt that degen-
eration itself can initiate a secondary autoimmune response 
within the CNS, mainly from the microglia whose proliferation 
in SPMS is very high even without morphological indica-
tors of haematogenic inflammation [57]. Due to the severity 
and extent of neurodegenerative changes, the ‘vicious circle’ 
mechanism (inflammation-neurodegeneration-inflammation) 
is particularly likely in SPMS.
Blood-brain barrier 
Compared to RRMS, some of the most significant chang-
es in SPMS are related to the BBB. The permeability of the 
damaged BBB with inflammatory activity is primarily related 
to the rim of the lesions with an increase in the number of 
chronic active plaques. Studies of the activity of BBB perme-
ability markers in SPMS suggest the resealing of the BBB. If 
this is the case, then ongoing inflammation in SPMS is at least 
partly compartmentalised behind an intact BBB, which hinders 
or even prevents the penetration of drugs into the CNS [25]. 
Objective vs subjective definitions of SPMS 
The division into the basic MS phenotypes (RRMS, prima-
ry progressive MS, SPMS) has been used for several decades. 
Definitions for the diagnosis of RRMS and PPMS (primary 
progressive multiple sclerosis) have been extensively defined 
using the 2017 revision of the McDonald criteria [58]. Unfortu-
nately, no uniform definition of SPMS has been established yet. 
The challenges associated with establishing a definition of 
SPMS result from difficulties related to the following factors: 
determining the degree of disability progression using the 
EDSS, determining the minimum score on the EDSS, deter-
mining the minimum degree and selecting the functional 
subscale, deciding on the necessity for the presence or absence 
of relapses, confirming disability progression at different time 
intervals (3-, 6-, 12- and 24-month intervals), determining the 
minimum time from the diagnosis of RRMS (usually at least 
24 months and mostly 36 months) and determining irrevers-
ibility of disease progression. 
To date, more than 570 definitions of SPMS have been 
presented. However, none has been commonly accepted. The 
existing definitions of SPMS are obtained from clinical trials 
and two significant manuscripts. Activities aimed at establish-
ing the definition are based on these [3, 30]. 
One of the main difficulties in defining SPMS is the lack of 
easily reproducible and sensitive-to-change outcome measures 
in a relatively short time. Moreover, these measures should 
reflect the pathology causing irreversible physical disability 
typical of disease progression i.e. axonal damage or loss. In 
practice, the common outcome measures for SPMS are clinical 
and imaging outcome measures. The objective vs subjective 
definitions of SPMS are set out in Table 1. 
The lack of a systematic definition of SPMS means that 
the inclusion criteria are not homogeneous, which hinders the 
interpretation of clinical trials [2, 21, 59]. Lorscheider et al. 
attempted to form a uniform definition based on the EDSS, FS, 
and the time necessary to confirm the diagnosis. The choice of 
such a definition allowed the establishment of a diagnosis three 
years earlier compared to retrospective physician evaluation. 
However, this definition did not consider MRI examinations, 
which made it difficult to clearly assess the disease activity. 
However, Lorscheider et al. emphasised that they wanted the 
definition to be easy and accessible [30]. 
When SPMS is described, the following definitions can 
be used: a “progressive disease” defined as steadily increas-
ing, objectively documented, neurological dysfunction; and 
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Table 1. Proposed diagnosis of SPMS




EDSS The most commonly used criteria 
in clinical trials
Limitations and problems re-
lated to objective definition
 — Worsening of 
baseline state 
between relapses 
 — Retrospective 
confirmation
Lorscheider et al. proposed definition of 
SPMS as:
 — disability progression by 1 step on EDSS 
in patients with EDSS ≤ 5.5 or 0.5 EDSS 
steps in patients with EDSS ≥ 6
 — no relapses
 — minimum EDSS score of 4
 — pyramidal functional system (FS) score 
of 2
 — confirmed progression over ≥ 3 months
 — including confirmation within the 
leading FS
 — SPMS patients who scored 3.0–6.5 
on EDSS
 — Evidence of secondary progression 
over at least the previous 2 years
 — Confirmed disability progression 
— an increase of 1.0 point on EDSS 
or an increase of 0.5 points if EDSS 
was 5.5 or more  
 — The limitation is the non-linearity 
of the EDSS scale
 — Probably the definition should 
include not only EDSS score but 
also FS score
 — 3-month follow-up is very short,  
in the opinion of experts
MRI Less frequently used criteria in clinical 
trials
Limitations and problems related to 
objective definition
 — Grey matter atrophy 
 — Total brain atrophy
 — Spinal cord atrophy (loss of cervical 
axons)
 — SPMS patients who scored 4.5–7.0 
on EDSS
 — Progression was defined as 
sufficient to change FS on EDSS 
or effect a meaningful functional 
change
 — No evidence of relapse within  
3 months prior to enrollment
 — Progressively worsened over the 
past 3 or 6 months
 — Disease activity was assessed by 
the onset of relapse or imaging 
results 
 — Most definitions did not include 
ARR or MRI changes in the diagno-
sis of SPMS [21, 30]
 — The exclusion of patients with 
more relapses after diagnosis may 
not have a significant effect on the 
diagnosis [30]
 — The frequency of relapses and Gd+ 
lesions is lower than in RRMS [30, 
70–72]
Biomarker of CSF and blood
 — Light chains of neurofilaments
 — Axonal tubulin and actin 
 — Glial fibrillary acidic protein (GFAP)  
 — S100B
New diagnostic method
 — Diffusion tensor imaging (DTI) 
 — Magnetisation transfer ratio (MTR)
 — Retinal nerve fibre layer (RNFL) and gan-
glion cell layer (GCL) assessed by OCT
“confirmed progression” defined as increased neurological dys-
function over a certain period of time (e.g. 3, 6 or 12 months) 
[2]. Clinical progression is not uniform, but may plateau and 
be characterised by periods of relative stability. The precise 
moment of transition from RRMS to SPMS is difficult in prac-
tice. Usually, the diagnosis of SPMS is made by neurologists 
retrospectively after several years of documented continuous 
neurological worsening. 
An objective definition based on the EDSS and the FS 
would be useful in predicting the course of the disease. It seems 
to be particularly helpful in the systematisation of clinical 
trials. However, this definition does not include MRI imaging. 
Importantly, radiological progression in SPMS has not been 
clearly established [60]. It is known that Gd+ lesions occur less 
frequently. However, an increase in the number and volume 
of T1 lesions, a decrease in the brain volume, and changes in 
diffusion tensor imaging and magnetic transfer imaging, are 
more common [60].
It has been established that a minimum degree of disability 
is required to diagnose SPMS, whereas RRMS and SPMS are 
a continuum because relapses can occur in both forms [2, 29, 
30, 61]. However, the annual relapse rate (ARR) during SPMS 
has been shown to be insignificant (0.23–0.26) [21]. Moreo-
ver, most definitions do not include ARR in the diagnosis of 
SPMS [21, 30].
Lorscheider et al. proposed a definition that most experts 
currently consider the most appropriate for the diagnosis of 
SPMS. This is as follows: disability progression by 1 EDSS step 
in patients with EDSS ≤ 5.5 or by 0.5 EDSS steps in patients 
with EDSS ≥ 6 in the absence of a relapse, a minimum EDSS 
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score of 4 and pyramidal FS score of 2, and confirmed progres-
sion over ≥ 3 months, including confirmation within the lead-
ing FS. The accuracy of this diagnosis is 87%, as confirmed by 
three independent raters. Furthermore, it should be confirmed 
in the same FS to minimise the period of uncertainty (about 
two years) from the first symptoms to the final diagnosis [30]. 
In our opinion, the definition proposed by Lorscheider et 
al. most closely matches the assessment of SPMS. To confirm 
disease progression, it is important to obtain a minimal EDSS 
score and pyramidal FS score. The use of FS allows improve-
ment in the internal validity of EDSS scores. The assessment 
of relapses after the diagnosis of SPMS does not affect the 
accuracy of the diagnosis [30]. However, we should be aware 
that the diagnosis of SPMS and its differentiation from other 
gradually progressive neurological disorders can remain elu-
sive, being based mainly on clinical evaluation, without any 
fully reliable diagnostic tools e.g. MRI.  
The question has also been posed as to whether SPMS 
occurs when progression between relapses is observed, or 
when the level of disability after another relapse is higher than 
after the previous relapse. Relapse-independent progression 
and relapse-related progression are both observed. However, 
as defined above, progression includes higher EDSS scores 
irrespective of relapse. The objective definition seems to be 
more sensitive than the diagnosis established by physicians 
(89% vs. 61%), which allows more frequent diagnosis of SPMS 
in future follow-up studies (18% vs. 9%) [4, 30]. It was found 
that in patients diagnosed with the use of the objective defi-
nition, a higher number of relapses was observed compared 
to those diagnosed by neurologists. This is probably due to 
the retrospective evaluation and the desire to administer 
disease-modifying drugs in the absence of other treatment 
perspectives [30]. 
The artificial division into RRMS or SPMS frequently caus-
es problems during clinical trials. RRMS’s transition to SPMS 
is gradual. Indeed, the entire notion of ‘transition’ from RRMS 
to SPMS should be treated with extreme caution, because it 
suggests the existence of a transition zone known as the grey 
zone, which is a poorly defined term. Considering the criteria 
for immunomodulatory treatment, the patient is left in some 
sense without a diagnosis. 
Therefore, it should rely particularly on the presence or ab-
sence of gradual progression and the presence of acute inflam-
mation (i.e. active lesions and relapses) [62, 63]. Worsening of 
ambulation, cognition, gait balance, muscle strength, visual 
symptoms, bladder symptoms and fatigue have been reported 
by patients and clinicians to be related to the progression from 
RRMS to SPMS. Additionally, it should be borne in mind that 
disease progression can be accelerated by obesity, mental 
disorders, physical disability, and smoking [64]. However, no 
specific symptom definitively indicates progression to SPMS. 
It may be useful to discuss the EDSS itself as a marker 
of progression. As previously mentioned, the higher the 
EDSS score, the lower the possibility of delay of disability 
progression [30]. Therefore, patients with a higher EDSS must 
be carefully monitored. 
For example, post hoc analysis of the FREEDOMS trials 
showed that an EDSS-based definition may be more reliable 
than MRI lesion activity and relapses. SPMS was diagnosed 
when the EDSS score was assessed within six months in the 
absence of relapses or with relapses and when the initial EDSS 
≥ 3.0 (increase by ≥ 1 for EDSS of 3–5 or by ≥ 0.5 for EDSS 
≥ 5.5). The study revealed that EDSS scores were significantly 
predictive of conversion to SPMS, particularly the higher base-
line EDSS > 3.5 [65]. Currently, the EDSS is the most widely 
used scale in MS clinical trials. It is an ordinal, nonlinear 
scale with high inter-rater variability and an overemphasis on 
walking ability. It should be noted that it can underestimate 
the scores related to cognition function, bladder dysfunction 
and upper extremity function, which is particularly crucial 
for the SPMS population. 
The most important sign of SPMS is increasing motor dys-
function, independently of relapse-associated progression. The 
use of the EDSS to confirm the diagnosis of SPMS is consistent 
with the concept of a neurodegenerative length-dependent 
axonopathy as a central component of progressive MS [66, 67]. 
Basically, disability progression in the EDSS is expressed by 
an increase of 0.5 or 1 step over 3 or 6 months. As mentioned, 
at some level (mostly EDSS 6), patients persist for a long time 
despite overall disease progression. Therefore, the baseline 
EDSS score and progression over time seem important [62, 63].
All these limitations of the EDSS can be problematic. 
A definition based only on the clinical assessment (e.g. on 
the EDSS in the diagnosis of SPMS) could be insufficient. 
Research is ongoing to find biomarkers based on imaging and 
biochemical data (e.g. in blood or in CSF) that could be used 
for early identification of transformation in SPMS. 
Progressive worsening of the baseline condition between 
relapses usually indicates transformation into SPMS [30]. As-
sessing this progression can be difficult due to the limitations 
of the EDSS. As already mentioned, the scale is mainly based 
on ambulation ability with EDSS scores > 4, and does not allow 
adequate assessment of upper limb function or cognitive func-
tion. The EDSS is characterised by variable results obtained 
by the same rater and by different raters [30]. 
Therefore, new diagnostic criteria are required. CSF mark-
ers are increasingly being mentioned in terms of facilitating 
the diagnosis. Light chains of neurofilaments (NfL) could be 
a potential indicator of disease progression, and their concen-
tration correlates positively with the EDSS [68–70]. Higher 
serum NfL levels have been observed in patients with SPMS 
compared to patients with RRMS of the same age. Patients with 
high serum NfL concentrations are exposed to an increased 
risk of conversion compared to patients with low serum NfL 
concentrations (based on the FREEDOMS and TRANSFORMS 
studies). Other molecules that can be used as markers of astro-
cytic damage include axonal tubulin and actin, glial fibrillary 
acidic protein (GFAP), and S100B [71–73]. 
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The objective definition can precede the diagnosis by many 
years. It seems that such a definition could contain both clini-
cal and radiological data as well as laboratory test results [2].
Diagnosing SPMS in clinical practice
Practical tools that will help predict the transition from 
RRMS to SPMS could be most beneficial to the everyday 
clinical practice of physicians. As already mentioned, the 
form of SPMS is mainly diagnosed retrospectively based on 
a gradual worsening of the patient’s condition after a history 
of initial relapses with or without acute exacerbations during 
disease progression. 
During follow-up visits, continuous assessment of patients 
for a gradual increase of symptoms not resulting from relapses 
(irreversible and persistent symptoms) seems to be the most 
important. Continued patient care by the same physician could 
be crucial. However, one study reported a 30% risk of overes-
timation of permanent disability assessed every 3–6 months 
[19], which could also pose a diagnostic challenge. 
The use of an objective definition could reduce this prob-
lem. However, it can be difficult and complicated in everyday 
practice. There is a need to further explore the diagnostic 
problem related to SPMS.
Physicians should note the frequency of relapses. Leray et 
al. found that a high relapse rate within 2–5 years of a diagnosis 
of MS significantly increased the risk of conversion to SPMS 
and the risk of progression [74, 75]. Furthermore, relapses 
in chronic MS significantly increase disability progression 
[76]. Paz Soldán et al. presented clinical features affecting 
post-progression disability accumulation. Both pre- and 
post-progression relapses increase the rate of post-progression 
disability accumulation. Women accumulate disability slightly 
faster in the early stages of the progressive disease. Progressive 
MS occurs from the age of 50, and slightly increases the rate 
of post-progression disability accumulation [76]. 
On the other hand, the risk factors for the progressive form 
of the disease or shorter transformation time in SPMS include 
male sex and motor symptoms at the time of the disease [77–
79]. As already mentioned, the duration of the disease is also 
important because within 20 years of diagnosis, conversion 
from RRMS to SPMS occurs in 30-60% of cases [77]. 
Compared to RRMS patients, subjects with the progressive 
form of the disease are usually older, have a higher degree of dis-
ability, a smaller number of Gd + lesions on T1-weighted images, 
and a larger volume of lesions on T2- weighted images [80–85].
Directions after diagnosis of SPMS
After diagnosis of SPMS, it is necessary to assess the 
course of the disease. It is assumed that disease progression 
should be assessed annually, regardless of relapse. There is no 
consensus as to how often MRI imaging should be performed. 
The disease may be stable over time [86, 87]. Experts have 
demonstrated that the degree of recovery after relapse is not 
useful in determining the phenotype of the disease. However, 
residual disability contributes to the worsening of the disease 
over time [60].
The primary goal of any proposed treatment for SPMS 
should be the prevention or delay of the accumulation of 
disability. 
Disease activity expressed by relapse rates and new changes 
on MRI can be used to describe SPMS. Experts recommend the 
terms ‘active’ (in the case of Gd+ lesions on MRI or relapse) 
and ‘progressive’ (when clinical symptoms progress) [60]. As 
the data shows, inflammatory processes occur in all MS sub-
types [88]. Treatment should start with the anti-inflammatory 
component. It is difficult to analyse SPMS in animal models. 
Therefore, the correct definition of SPMS could be useful in the 
proper conduct of clinical trials and in testing new drugs [4].
Treatment of SPMS is very problematic. This subtype is 
diagnosed late, CNS damage is advanced, and most drugs are 
ineffective. Furthermore, difficulty in determining the clinical 
benefits of the drug should be also stressed. It is very difficult 
to demonstrate such benefits, especially if the aim is not to 
prolong life but rather to postpone disability. The term ‘time 
to wheelchair’ is used to determine this aim. Some studies 
have revealed that the use of immunomodulatory therapy in 
the phenotype with relapses may delay the development of 
SPMS [76, 79]. However, research on this topic is not conclu-
sive [76]. The treatment of SPMS still remains a significant 
problem to solve.
In the absence of alternative therapies, physicians could 
extend the treatment initiated in patients with RRMS symp-
toms who already have the SPMS phenotype. The accurate 
definition of SPMS would allow earlier diagnosis, faster testing 
of new drugs, and thus better treatment results. Establishing 
the right definition is crucial for further research into the 
treatment of SPMS.
As already mentioned, it is important whether the di-
agnosis is established by physicians or is based on criteria 
such as the EDSS. This can make a difference in diagnosis 
of as much as five years [62, 63]. Initially, the inflammatory 
processes can prevail despite the progressive form. In future, 
patients with a shorter duration of SPMS or early diagnosis 
will have different treatment perspectives compared to those 
with a longer course of the disease. 
To date, the clinical results with dimethyl fumarate and 
natalizumab in patients with SPMS have not confirmed their 
effectiveness. Interferon beta has only been registered in 
Europe for the treatment of patients with active SPMS [8]. 
None of the drugs approved for RRMS has been shown to 
consistently decrease the progression of disability in SPMS 
as assessed by the EDSS. 
In 2015, Ontaneda et al. showed in their study that nearly 
20 compounds had been included in clinical trials within 
a period of five years [21]. Other substances that have been 
tested in the treatment of SPMS are discussed below. 
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The issue of vitamin D levels in MS patients is of crucial 
importance and may be significant in the treatment of SPMS. 
Research shows that high levels of this vitamin may have pro-
tective effects on myelin in normal-appearing grey and white 
matter [89]. Interestingly, another study showed a single case 
of SPMS regression following a ketogenic diet [90].
The MS-STAT randomised, placebo-controlled trial 
revealed that high-doses of simvastatin reduced total brain 
atrophy and improved the quality of life in patients with SPMS 
[91]. The inclusion criteria were as follows: age 18-65, EDSS 
4.0–6.5, and a diagnosis of MS based on the McDonald criteria 
(2017) with evidence of secondary progression over at least the 
previous two years. None of the patients was treated with dis-
ease-modifying drugs. These criteria did not include accurate 
information on the diagnosis of SPMS. The authors suggested 
a minimum period of two years of confirmed progression [91].
The recent EXPAND study has revealed the effectiveness of 
siponimod, i.e. sphingosine 1-phosphate (S1P) receptor mod-
ulator selective for S1P1 and S1P5 receptors. This molecule 
has been shown to reduce the risk of disability progression 
in patients with SPMS [16]. Another study confirmed the 
effectiveness of siponimod in patients with SPMS (particu-
larly those with the active form). Furthermore, siponimod 
has shown neuroprotective effects [92]. That study included 
patients with SPMS and documented disease progression over 
the past two years in the absence of relapses or regardless of 
relapses, no evidence of relapse within three months prior 
to enrollment, and a median EDSS score of 3.0 to 6.5 at the 
time of inclusion in the study. Patients aged over 61 were not 
included in the study. In terms of disease activity, the char-
acteristic features of inflammatory activity in SPMS may be 
associated with a relapse or imaging results (i.e. Gd+ lesions 
on T1- weighted images or active [new or enlarged] lesions 
on T2- weighted images) [16].
Mitoxantrone (MTX) is one of the approved forms of 
treatment for SPMS. It is used for EDSS scores of 3 to 6 [93]. 
The effectiveness of MTX administration has been confirmed 
by long- and short-term follow-ups [93, 94]. 
The potential risk of serious adverse events after MTX 
treatment, such as cardiotoxicity and acute leukaemia related 
to treatment, is also significant. It develops its effect on the 
immune system by reducing the number of T lymphocytes, 
the activity of cytotoxic T lymphocytes, inhibiting humoral 
immunity and the secretion of Th1 cytokines. As a result, it 
has a strong immunosuppressive effect. Overall, MTX can be 
considered as a form of therapy for very active MS, especially 
in regions with limited access to new immunotherapy [95]. 
High doses of biotin, which has neuroprotective proper-
ties [96, 97], may be used in the future for the treatment of 
SPMS. A randomised, double-blind, placebo-controlled study 
revealed a decrease in progression as assessed by the EDSS and 
a high safety profile of this treatment [97]. Patients included in 
this study (aged 18–75) were diagnosed with PPMS or SPMS 
using the revised McDonald criteria with clinical evidence of 
spastic paraparesis. Patients with clinical or radiological evi-
dence of inflammatory activity within the previous year were 
excluded. Eligible patients had a baseline EDSS of 4.5–7 with 
evidence of disease progression during the previous two years 
(an increase of ≥ 1 point if the EDSS was 4.5–5.5 or ≥ 0.5 points 
if the EDSS was 6–7) [97].
Other molecules that may be important in the treatment of 
SPMS include alpha-lipoic acid [98]. The inclusion criteria in 
this study were as follows: age 40–70, prior RRMS (2005 Mc-
Donald criteria), and current SPMS defined by MS disability 
progression in the absence of clinical relapse during the 
previous five years as determined by a physician. Progression 
was defined as sufficient to change the FS on the EDSS or to 
effect a meaningful functional change (e.g. stopped working 
due to cognitive decline). Participants were allowed to start, 
stop, or continue glatiramer acetate or β-interferon during 
the study [98].
It is worth noting that SPMS and PPMS have been ana-
lysed together in most studies, leading to some difficulties in 
interpreting study results. The differential diagnosis between 
PPMS and SPMS is often based on a patient’s ability to recall 
previous episodes of a neurological symptom, these being 
sometimes very mild and therefore overlooked. The authors 
of various publications have used different eligibility criteria 
for clinical trials for patients with SPMS. The inclusion criteria 
for various studies are set out in Table 2. 
The results of selected studies on the use of immunomodu-
latory therapy in patients with SPMS have also been presented 
[81, 99–105]. It can be difficult to establish the definition of 
SPMS based on the conducted research. Regardless of treat-
ment effectiveness, most researchers include patients with 
SPMS and an EDSS of 3-6.5 [16, 81, 100, 103]. To confirm 
progression, different time intervals were used in the studies 
(i.e. 3, 6, 12, or 24 months). In positive studies with siponi-
mod, mitoxantrone and interferon beta, the criterion of 12, 
6 or 3 months was used, respectively [16, 93, 100]. However, 
in negative trials with interferon beta and natalizumab, the 
criterion of 3 or 24 months was used, respectively [81, 103]. 
The most commonly accepted time to confirm a deficit assessed 
by the EDSS is 3 or 6 months [60]. Most of the studies set out 
in Table 2 did not exclude patients with relapses. However, in 
the study with siponimod, the eligibility criteria included no 
evidence of relapse in the three months before inclusion in 
the study. Objective definitions assessing disease progression 
using minimal EDSS levels seem to be more stable [30, 106]. 
Typically, disability progression has been defined as an increase 
of 1 point in the EDSS or an increase of 0.5 points if the EDSS 
was 5.5 or more [93, 97, 100, 103]. Patients with SPMS can 
experience not only relapses but can also present with Gd + 
MRI lesions. However, the frequency of relapses and Gd + 
lesions is lower than in RRMS (29-70%) [30, 107–109]. In the 
presented research, only the study with siponimod assessed 
disease activity on MRI as part of the inclusion criteria. The 
main limitation of most studies was the non-linearity of the 
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Table 2. Examples of eligibility criteria for clinical trials for patients with SPMS and results of selected studies on use of immunomodulatory therapy in 
patients with SPMS
Study Proposed inclusion criteria Immunomodulatory drugs te-
sted in the treatment of SPMS
Result of primary  
endpoint
Chan, D., et al., 2017 
(MS-STAT)
 — Age 18–65
 — EDSS 4.0–6.5 
 — Diagnosis of MS based on 2017 McDonald criteria
 — Evidence of secondary progression over at least 
the last 2 years
High-doses of simvastatin Reduced total brain 
atrophy and improved 
quality of life in patients 
with SPMS
Kappos, L., et al., 2018 
(EXPAND)
 — Age 18–60 
 — SPMS diagnosis 
 — Documented disease progression during the 
previous 2 years in the absence of relapses, or 
regardless of relapses
 — No evidence of relapse within 3 months prior to 
enrollment
 — Median score of 3.0 to 6.5 on EDSS at time of 
entry into study
 — Disease activity assessed by the onset of relapse 
or imaging results (i.e. Gd+ lesions on T1-weig-
hted images or active [new or enlarged] lesions 
on T2- weighted images)
Siponimod Reduced risk of disability 
progression
Tourbah, A., et al., 2016 
(MD 1003)
 — Age 18–75 
 — PPMS or SPMS patients who were diagnosed 
using revised McDonald criteria 
 — Clinical evidence of spastic paraparesis 
 — Patients with clinical or radiological evidence of 
inflammatory activity within the previous year 
were excluded from the study
 — EDSS 4.5–7
 — Evidence of disease progression during the pre-
vious 2 years (an increase of ≥ 1 point if EDSS was 
4.5–5.5 or of ≥ 0.5 points if EDSS was 6–7)
High doses of biotin Decrease in progression 
as assessed by EDSS, and 
high safety profile of this 
treatment
Spain, R., et al., 2017  — Age 40–70, prior RRMS (2005 McDonald criteria)
 — Current SPMS defined by MS disability progres-
sion in the absence of clinical relapse during the 
previous 5 years as determined by a physician
 — Progression was defined as sufficient to change 
the FS on the EDSS or effect a meaningful functio-
nal change 
Alpha-lipoic acid 68% reduction in annual-
ised percent change brain 
volume  
Lancet, 1998  — SPMS patients who scored 3.0-6.5 on the EDSS 
 — Confirmed disability progression (increase of 1.0 
point on the EDSS or of 0.5 points if the EDSS was 
6.0 or 6.5 for at least 3 months)
IFNβ-1b European study was 
positive 




 — SPMS patients 
 — EDSS between 3.0 and 6.5 
 — Progressively worsened over the past 6 months
 — Confirmed disability progression (an increase of 
1.0 point on EDSS or of 0.5 points if EDSS was 5.5 
or more for at least 3 months)
IFNβ-1a SPECTRIMS study was 
negative
Study conducted by 
Nordic SPMS Study Group 
gave a negative result
Kapoor, R., et al., 2018 
(ASCEND)
 — Age 18–58 
 — SPMS for 2 years or more
 — Disability progression unrelated to relapse in the 
previous year
 — EDSS 3.0–6.5
Natalizumab ASCEND study was nega-
tive
Martinelli Boneschi, F., 
et al., 2013 
(MITOX, MIMS)
 — Adult patients with SPMS
 — Regardless of age, gender, disability and duration 
of disease
 — Disability progression defined as increase by at 
least 1 point if EDSS < 5.5 or at least 0.5 points if 
EDSS > 5.5
 — EDSS assessed in two different and subsequent 
neurological examinations separated by at least 
a 6-month interval free of relapses
Mitoxantrone Mitoxantrone reduced the 
progression of disability at 
two-year follow-up
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EDSS as it focuses on motor and lower limb functions, which 
can reduce the detection of subtle disease symptoms [30, 
110]. On the other hand, a more stringent definition should 
include not only the EDSS score but also the FS, although the 
authors of the recommendations considered the possibility 
of deterioration or improvement within a different FS score 
with the same EDSS score [2]. Most studies did not use FS 
as an inclusion criterion. It is possible that the use of FS may 
improve the accuracy of the SPMS definition in the future. 
A gradual increase in time from diagnosis of MS to conversion 
to SPMS has been observed [111–116]. This may be associated 
with the MS phenotype, new drugs, or the heterogeneity of 
observational studies [22]. In studies with interferons, the time 
to progression was three months; in the case of siponimod it 
was two years [16, 100, 103]. 
Summarising the oldest studies with interferons, the 
inclusion criteria were very similar regardless of treatment 
effectiveness [100, 103]. Studies with mitoxantrone gave gen-
erally positive results in short and long-term follow-ups [11, 
94]. The inclusion criteria for the study were very similar to 
those in the study with interferons [100, 103]. The study with 
siponimod considered changes on MRI. Most of the analysed 
studies did not take into account changes in FS in their criteria. 
The criterion of the mean EDSS (3–6.5) at the time of entry 
into the study was very constant [16, 81, 100, 103]. 
The authors used the definition of Lorscheider et al. After 
analysing a large group of studies, there are many inaccuracies 
that will require further research. Many compounds are under 
investigation, and new possibilities should be revealed in the 
future. Therefore, it is important to establish clear diagnostic 
criteria for SPMS to facilitate further research [8]. 
It has been reported that SPMS onset could be related 
to the most appropriate therapy model in RRMS. The most 
recent study proved that among patients with RRMS, initial 
treatment with highly active drugs (i.e. fingolimod, alemtu-
zumab, or natalizumab) was associated with a lower risk 
of conversion to SPMS compared to initial treatment with 
glatiramer acetate or interferon beta [117]. On the other 
hand, the rate of disability progression after the onset of 
SPMS was not associated with early disease course or treat-
ment decisions. Relapses during SPMS were associated with 
accelerated disability progression, and immunomodulatory 
therapy was associated with improvements in disability 
outcomes in these patients. 
These results confirm that inflammatory disease activity 
remains a substantial yet modifiable component of SPMS [118].
Summary 
Two mechanisms are closely related to the development of 
SPMS: immune-inflammatory and neurodegenerative. Clin-
ically, a gradual transition from RRMS to a progressive form 
of MS is observed. The authors of this article often struggled 
with the problem of diagnosing SPMS. 
To facilitate the work of other physicians, we have created 
an overview of the available data on the SPMS definition. In our 
opinion, it seems that combining patient observation and sys-
tematic visits with available SPMS definitions may be helpful. 
Current knowledge has not provided us with official SPMS 
criteria, as opposed to RRMS and PPMS forms (where we have 
the 2017 McDonald criteria). It seems that a definition which 
does not include MRI or other biomarkers might not be suffi-
cient. Establishing the criteria for the diagnosis of SPMS is very 
important due to current and future treatment possibilities. 
It is reasonable to introduce drugs at the earliest possible 
stage of lesion progression to reduce inflammation and protect 
the CNS from irreversible neurodegeneration [36, 119]. The 
updated criteria should include various aspects of this form. 
It is possible that this will be based on modern technologies 
such as diffusion tensor imaging (DTI), magnetisation transfer 
ratio (MTR), RNFL, and a better understanding of the patho-
mechanism affecting the development of this phenotype of MS.
Ethical permission: Ethical approval was not necessary for the 
preparation of this article.
Funding: The authors received no funding for this study.
References
1. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers 
in neurological disorders. Nat Rev Neurol. 2018; 14(10): 577–589, 
doi: 10.1038/s41582-018-0058-z, indexed in Pubmed: 30171200.
2. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of 
multiple sclerosis: the 2013 revisions. Neurology. 2014; 83(3): 278–
286, doi: 10.1212/WNL.0000000000000560, indexed in Pubmed: 
24871874.
3. Lublin FD. New multiple sclerosis phenotypic classification. Eur Neu-
rol. 2014; 72 Suppl 1: 1–5, doi: 10.1159/000367614, indexed in 
Pubmed: 25278115.
4. Mahad D, Trapp B, Lassmann H. Pathological mechanisms in pro-
gressive multiple sclerosis. The Lancet Neurology. 2015; 14(2): 183–
193, doi: 10.1016/s1474-4422(14)70256-x.
5. Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute 
multiple sclerosis lesions. Brain. 1997; 120 ( Pt 3): 393–399, doi: 
10.1093/brain/120.3.393, indexed in Pubmed: 9126051.
6. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in 
the lesions of multiple sclerosis. N Engl J Med. 1998; 338(5): 278–
285, doi: 10.1056/NEJM199801293380502, indexed in Pubmed: 
9445407.
7. Bjartmar C, Kidd G, Mark S, et al. Neurological disability correlates with 
spinal cord axonal loss and reducedN-acetyl aspartate in chronic mul-
tiple sclerosis patients. Annals of Neurology. 2001; 48(6): 893–901, 
doi: 10.1002/1531-8249(200012)48:6<893::aid-ana10>3.0.co;2-b.
8. Baldassari LE, Fox RJ. Therapeutic Advances and Challenges in the 
Treatment of Progressive Multiple Sclerosis. Drugs. 2018; 78(15): 
1549–1566, doi: 10.1007/s40265-018-0984-5, indexed in Pubmed: 
30255442.
9. Ruano L, Portaccio E, Goretti B, et al. Age and disability drive cognitive 
impairment in multiple sclerosis across disease subtypes. Mult Scler. 
2017; 23(9): 1258–1267, doi: 10.1177/1352458516674367, inde-
xed in Pubmed: 27738090.
395www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Monika Adamczyk-Sowa et al., Secondary progressive multiple sclerosis 
10. Curti E, Graziuso S, Tsantes E, et al. Correlation between cortical 
lesions and cognitive impairment in multiple sclerosis. Brain Behav. 
2018; 8(6): e00955, doi: 10.1002/brb3.955, indexed in Pubmed: 
29974667.
11. Andreasen AK, Iversen P, Marstrand L, et al. Structural and cognitive 
correlates of fatigue in progressive multiple sclerosis. Neurol Res. 
2019; 41(2): 168–176, doi: 10.1080/01616412.2018.1547813, in-
dexed in Pubmed: 30513278.
12. Højsgaard Chow H, Schreiber K, Magyari M, et al. Progressive mul-
tiple sclerosis, cognitive function, and quality of life. Brain Behav. 
2018; 8(2): e00875, doi: 10.1002/brb3.875, indexed in Pubmed: 
29484253.
13. Kizlaitienė R, Kaubrys G, Giedraitienė N, et al. Composite Marker of 
Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discrimi-
nating Between Relapsing-Remitting and Secondary Progressive Mul-
tiple Sclerosis. Med Sci Monit. 2017; 23: 588–597, doi: 10.12659/
msm.903234, indexed in Pubmed: 28145395.
14. Carotenuto A, Costabile T, Moccia M, et al. Olfactory function and 
cognition in relapsing-remitting and secondary-progressive multiple 
sclerosis. Mult Scler Relat Disord. 2019; 27: 1–6, doi: 10.1016/j.
msard.2018.09.024, indexed in Pubmed: 30273697.
15. Connick P, Chandran S, Bak T. Patterns of Cognitive Dysfunction in 
Progressive MS. Behavioural Neurology. 2013; 27(3): 259–265, doi: 
10.1155/2013/743878.
16. Kappos, L., A. Bar-Or, B.A.C. Cree, R.J. Fox, G. Giovannoni, R. Gold, P. 
Vermersch, D.L. Arnold, S. Arnould, T. Scherz, C. Wolf, E. Wallstrom, F. 
Dahlke, and E.C. Investigators, Siponimod versus placebo in seconda-
ry progressive multiple sclerosis (EXPAND): a double-blind, randomi-
sed, phase 3 study. Lancet. 2018; 391: 1263–1273.
17. Franklin RJM, Ffrench-Constant C. Remyelination in the CNS: from 
biology to therapy. Nat Rev Neurosci. 2008; 9(11): 839–855, doi: 
10.1038/nrn2480, indexed in Pubmed: 18931697.
18. BROWNELL B, HUGHES JT. The distribution of plaques in the cerebrum 
in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962; 25: 315–
320, doi: 10.1136/jnnp.25.4.315, indexed in Pubmed: 14016083.
19. Peterson JW, Bö L, Mörk S, et al. Transected neurites, apoptotic neu-
rons, and reduced inflammation in cortical multiple sclerosis lesions. 
Ann Neurol. 2001; 50(3): 389–400, doi: 10.1002/ana.1123, indexed 
in Pubmed: 11558796.
20. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelina-
tion and diffuse white matter injury in multiple sclerosis. Brain. 2005; 
128(Pt 11): 2705–2712, doi: 10.1093/brain/awh641, indexed in 
Pubmed: 16230320.
21. Ontaneda D, Fox R, Chataway J. Clinical trials in progressive multiple 
sclerosis: lessons learned and future perspectives. The Lancet Neuro-
logy. 2015; 14(2): 208–223, doi: 10.1016/s1474-4422(14)70264-9.
22. Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the 
natural history of multiple sclerosis. Neurology. 2010; 74(24): 2004–
2015, doi: 10.1212/WNL.0b013e3181e3973f, indexed in Pubmed: 
20548045.
23. Ontaneda D, Thompson A, Fox R, et al. Progressive multiple sclerosis: 
prospects for disease therapy, repair, and restoration of function. 
The Lancet. 2017; 389(10076): 1357–1366, doi: 10.1016/s0140-
6736(16)31320-4.
24. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: 
pathology and pathogenesis. Nat Rev Neurol. 2012; 8(11): 647–656, 
doi: 10.1038/nrneurol.2012.168, indexed in Pubmed: 23007702.
25. Lassmann H. Targets of therapy in progressive MS. Mult Scler. 2017; 
23(12): 1593–1599, doi: 10.1177/1352458517729455, indexed in 
Pubmed: 29041864.
26. Nakamura K, Fox R, Fisher E. CLADA: cortical longitudinal atrop-
hy detection algorithm. Neuroimage. 2011; 54(1): 278–289, doi: 
10.1016/j.neuroimage.2010.07.052, indexed in Pubmed: 20674750.
27. Nakamura K, Guizard N, Fonov VS, et al. Jacobian integration method 
increases the statistical power to measure gray matter atrophy in 
multiple sclerosis. Neuroimage Clin. 2014; 4: 10–17, doi: 10.1016/j.
nicl.2013.10.015, indexed in Pubmed: 24266007.
28. Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multi-
ple sclerosis is most extensive in early disease stages and decreases 
over time. Brain. 2002; 125(Pt 10): 2202–2212, doi: 10.1093/brain/
awf235, indexed in Pubmed: 12244078.
29. Katz Sand I, Krieger S, Farrell C, et al. Diagnostic uncertainty during 
the transition to secondary progressive multiple sclerosis. Mult Scler. 
2014; 20(12): 1654–1657, doi: 10.1177/1352458514521517, inde-
xed in Pubmed: 24493475.
30. Lorscheider J, Buzzard K, Jokubaitis V, et al. MSBase Study Group. De-
fining secondary progressive multiple sclerosis. Brain. 2016; 139(Pt 
9): 2395–2405, doi: 10.1093/brain/aww173, indexed in Pubmed: 
27401521.
31. Petzold A, Boer Jde, Schippling S, et al. Optical coherence tomo-
graphy in multiple sclerosis: a systematic review and meta-analysis. 
The Lancet Neurology. 2010; 9(9): 921–932, doi: 10.1016/s1474-
-4422(10)70168-x.
32. Abalo-Lojo JM, Limeres CC, Gómez MA, et al. Retinal nerve fiber 
layer thickness, brain atrophy, and disability in multiple sclerosis 
patients. J Neuroophthalmol. 2014; 34(1): 23–28, doi: 10.1097/
WNO.0000000000000057, indexed in Pubmed: 24162258.
33. Saidha S, Syc SB, Durbin MK, et al. Visual dysfunction in multiple scle-
rosis correlates better with optical coherence tomography derived esti-
mates of macular ganglion cell layer thickness than peripapillary reti-
nal nerve fiber layer thickness. Mult Scler. 2011; 17(12): 1449–1463, 
doi: 10.1177/1352458511418630, indexed in Pubmed: 21865411.
34. Narayanan D, Cheng H, Bonem KN, et al. Tracking changes over time 
in retinal nerve fiber layer and ganglion cell-inner plexiform layer 
thickness in multiple sclerosis. Mult Scler. 2014; 20(10): 1331–1341, 
doi: 10.1177/1352458514523498, indexed in Pubmed: 24639478.
35. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of mul-
tiple sclerosis: an overview. Brain Pathol. 2007; 17(2): 210–218, 
doi: 10.1111/j.1750-3639.2007.00064.x, indexed in Pubmed: 
17388952.
36. Behrangi, N., F. Fischbach, and M. Kipp, Mechanism of Siponimod: 
Anti-Inflammatory and Neuroprotective Mode of Action. 2019: Cells.
37. Zhou, L., J.E. Lopes, M.M. Chong, Ivanov, II, R. Min, G.D. Victora, Y. 
Shen, J. Du, Y.P. Rubtsov, A.Y. Rudensky, S.F. Ziegler, and D.R. Littman, 
TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antago-
nizing RORgammat function. Nature. 2008; 453: 236–40.
38. Carlson T, Kroenke M, Rao P, et al. The Th17-ELR+ CXC chemoki-
ne pathway is essential for the development of central nervous sy-
stem autoimmune disease. J Exp Med. 2008; 205(4): 811–823, doi: 
10.1084/jem.20072404, indexed in Pubmed: 18347102.
39. Na SY, Hermann A, Sanchez-Ruiz M, et al. Oligodendrocytes enforce im-
mune tolerance of the uninfected brain by purging the peripheral reper-
toire of autoreactive CD8+ T cells. Immunity. 2012; 37(1): 134–146, 
doi: 10.1016/j.immuni.2012.04.009, indexed in Pubmed: 22683122.
40. Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular 
system that drains brain interstitial fluid and macromolecules. J Exp 
Med. 2015; 212(7): 991–999, doi: 10.1084/jem.20142290, indexed 
in Pubmed: 26077718.
41. Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional fe-
atures of central nervous system lymphatic vessels. Nature. 2015; 
396
Neurologia i Neurochirurgia Polska 2020, vol. 54, no. 5
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
523(7560): 337–341, doi: 10.1038/nature14432, indexed in 
Pubmed: 26030524.
42. Höftberger R, Lassmann H. Inflammatory demyelinating diseases of 
the central nervous system. Handb Clin Neurol. 2017; 145: 263–283, 
doi: 10.1016/B978-0-12-802395-2.00019-5, indexed in Pubmed: 
28987175.
43. Radick, L. and S.R. Mehr, The Latest Innovations in the Drug Pipeline 
for Multiple Sclerosis. Am Health Drug Benefits. 2015; 8: 448–53.
44. Hendrickx DAE, van Eden CG, Schuurman KG, et al. Staining of HLA-
-DR, Iba1 and CD68 in human microglia reveals partially overlapping 
expression depending on cellular morphology and pathology. J Neuro-
immunol. 2017; 309: 12–22, doi: 10.1016/j.jneuroim.2017.04.007, 
indexed in Pubmed: 28601280.
45. Park E, Gallezot JD, Delgadillo A, et al. (11)C-PBR28 imaging in multi-
ple sclerosis patients and healthy controls: test-retest reproducibility 
and focal visualization of active white matter areas. Eur J Nucl Med 
Mol Imaging. 2015; 42(7): 1081–1092, doi: 10.1007/s00259-015-
3043-4, indexed in Pubmed: 25833352.
46. Sádaba MC, Tzartos J, Paíno C, et al. Axonal and oligodendrocyte-
-localized IgM and IgG deposits in MS lesions. J Neuroimmunol. 2012; 
247(1-2): 86–94, doi: 10.1016/j.jneuroim.2012.03.020, indexed in 
Pubmed: 22531276.
47. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple 
sclerosis lesions. Brain. 2011; 134(Pt 7): 1914–1924, doi: 10.1093/
brain/awr128, indexed in Pubmed: 21653539.
48. Ciccarelli O, Barkhof F, Bodini B, et al. Pathogenesis of multiple sclero-
sis: insights from molecular and metabolic imaging. The Lancet Neuro-
logy. 2014; 13(8): 807–822, doi: 10.1016/s1474-4422(14)70101-2.
49. Gaitán MI, Shea CD, Evangelou IE, et al. Evolution of the blood-
-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol. 
2011; 70(1): 22–29, doi: 10.1002/ana.22472, indexed in Pubmed: 
21710622.
50. Singh S, Dallenga T, Winkler A, et al. Relationship of acute axonal da-
mage, Wallerian degeneration, and clinical disability in multiple scle-
rosis. J Neuroinflammation. 2017; 14(1): 57, doi: 10.1186/s12974-
017-0831-8, indexed in Pubmed: 28302146.
51. Datta S, Staewen TD, Cofield SS, et al. MRI Analysis Center at Houston, 
CombiRx Investigators Group. Regional gray matter atrophy in re-
lapsing remitting multiple sclerosis: baseline analysis of multi-center 
data. Mult Scler Relat Disord. 2015; 4(2): 124–136, doi: 10.1016/j.
msard.2015.01.004, indexed in Pubmed: 25787188.
52. Kuhlmann T, Ludwin S, Prat A, et al. An updated histological clas-
sification system for multiple sclerosis lesions. Acta Neuropathol. 
2017; 133(1): 13–24, doi: 10.1007/s00401-016-1653-y, indexed in 
Pubmed: 27988845.
53. Kearney H, Miller DH, Ciccarelli O. Spinal cord MRI in multiple 
sclerosis--diagnostic, prognostic and clinical value. Nat Rev Neurol. 
2015; 11(6): 327–338, doi: 10.1038/nrneurol.2015.80, indexed in 
Pubmed: 26009002.
54. Petrova N, Carassiti D, Altmann DR, et al. Axonal loss in the multiple 
sclerosis spinal cord revisited. Brain Pathol. 2018; 28(3): 334–348, 
doi: 10.1111/bpa.12516, indexed in Pubmed: 28401686.
55. Dekker I, Wattjes MP. Brain and Spinal Cord MR Imaging Features in 
Multiple Sclerosis and Variants. Neuroimaging Clin N Am. 2017; 27(2): 
205–227, doi: 10.1016/j.nic.2016.12.002, indexed in Pubmed: 
28391782.
56. Luchetti S, Fransen NL, van Eden CG, et al. Progressive multiple 
sclerosis patients show substantial lesion activity that correlates 
with clinical disease severity and sex: a retrospective autopsy cohort 
analysis. Acta Neuropathol. 2018; 135(4): 511–528, doi: 10.1007/
s00401-018-1818-y, indexed in Pubmed: 29441412.
57. Nowacki P, Koziarska D, Masztalewicz M. Microglia and astroglia 
proliferation within the normal appearing white matter in histologi-
cally active and inactive multiple sclerosis. Folia Neuropathol. 2019; 
57(3): 249–257, doi: 10.5114/fn.2019.88453, indexed in Pubmed: 
31588711.
58. Thompson A, Banwell B, Barkhof F, et al. Diagnosis of multiple scle-
rosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 
2018; 17(2): 162–173, doi: 10.1016/s1474-4422(17)30470-2.
59. Koch MW, Cutter G, Stys PK, et al. Treatment trials in progressive MS--
-current challenges and future directions. Nat Rev Neurol. 2013; 9(9): 
496–503, doi: 10.1038/nrneurol.2013.148, indexed in Pubmed: 
23897406.
60. Rudick RA, Kappos L. Measuring disability in relapsing-remit-
ting MS. Neurology. 2010; 75(4): 296–297, doi: 10.1212/
WNL.0b013e3181ecf815, indexed in Pubmed: 20592252.
61. Ebers GC, Heigenhauser L, Daumer M, et al. Disability as an outcome in 
MS clinical trials. Neurology. 2008; 71(9): 624–631, doi: 10.1212/01.
wnl.0000313034.46883.16, indexed in Pubmed: 18480462.
62. Lublin FD, Reingold SC. Defining the clinical course of multiple scle-
rosis: results of an international survey. National Multiple Sclerosis 
Society (USA) Advisory Committee on Clinical Trials of New Agents in 
Multiple Sclerosis. Neurology. 1996; 46(4): 907–911, doi: 10.1212/
wnl.46.4.907, indexed in Pubmed: 8780061.
63. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive 
multiple sclerosis: current knowledge and future challenges. The 
Lancet Neurology. 2006; 5(4): 343–354, doi: 10.1016/s1474-
4422(06)70410-0.
64. Marrie Ra, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic 
status and multiple sclerosis. Mult Scler. 2008; 14(8): 1091–1098, 
doi: 10.1177/1352458508092263, indexed in Pubmed: 18728060.
65. Tomic, D., L. Kappos, D.P. Meier, D. Häring, R. Meinert, G. Giovannoni, 
and T. Chitnis, Predictors of Conversion to Secondary Progressive Mul-
tiple Sclerosis in Patients With Relapsing–Remitting Multiple Sclerosis 
(P2. 393. ; 2018: AAN.
66. Lamers I, Feys P. Assessing upper limb function in mul-
tiple sclerosis. Mult Scler. 2014; 20(7): 775–784, doi: 
10.1177/1352458514525677, indexed in Pubmed: 24664300.
67. Brissart H, Sauvée M, Latarche C, et al. Integration of cognitive im-
pairment in the expanded disability status scale of 215 patients 
with multiple sclerosis. Eur Neurol. 2010; 64(6): 345–350, doi: 
10.1159/000322140, indexed in Pubmed: 21071951.
68. Malmeström C, Haghighi S, Rosengren L, et al. Neurofilament 
light protein and glial fibrillary acidic protein as biological markers 
in MS. Neurology. 2003; 61(12): 1720–1725, doi: 10.1212/01.
wnl.0000098880.19793.b6, indexed in Pubmed: 14694036.
69. Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF 
neurofilament light and heavy chain protein in MS. Mult Scler. 2013; 
19(12): 1597–1603, doi: 10.1177/1352458513482374, indexed in 
Pubmed: 23529999.
70. Gunnarsson M, Malmeström C, Axelsson M, et al. Axonal damage in 
relapsing multiple sclerosis is markedly reduced by natalizumab. Ann 
Neurol. 2011; 69(1): 83–89, doi: 10.1002/ana.22247, indexed in 
Pubmed: 21280078.
71. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axo-
nal cytoskeletal proteins in multiple sclerosis is associated with pro-
gressive disease and clinical disability. Journal of Neuroimmunology. 
2002; 122(1-2): 132–139, doi: 10.1016/s0165-5728(01)00455-6.
397www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Monika Adamczyk-Sowa et al., Secondary progressive multiple sclerosis 
72. Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial 
cell responses in multiple sclerosis: clinical and pathological corre-
lations. Brain. 2002; 125(Pt 7): 1462–1473, doi: 10.1093/brain/
awf165, indexed in Pubmed: 12076997.
73. Axelsson M, Malmeström C, Nilsson S, et al. Glial fibrillary acidic 
protein: a potential biomarker for progression in multiple sclerosis. J 
Neurol. 2011; 258(5): 882–888, doi: 10.1007/s00415-010-5863-2, 
indexed in Pubmed: 21197541.
74. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability 
progression in multiple sclerosis. Brain. 2010; 133(Pt 7): 1900–1913, 
doi: 10.1093/brain/awq076, indexed in Pubmed: 20423930.
75. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multi-
ple sclerosis: a geographically based study 10: relapses and long-term 
disability. Brain. 2010; 133(Pt 7): 1914–1929, doi: 10.1093/brain/
awq118, indexed in Pubmed: 20534650.
76. Paz Soldán MM, Novotna M, Abou Zeid N, et al. Relapses and disabi-
lity accumulation in progressive multiple sclerosis. Neurology. 2015; 
84(1): 81–88, doi: 10.1212/WNL.0000000000001094, indexed in 
Pubmed: 25398229.
77. Tremlett H, Devonshire V. Natural history of secondary-progressi-
ve multiple sclerosis. Mult Scler. 2008; 14(3): 314–324, doi: 
10.1177/1352458507084264, indexed in Pubmed: 18208898.
78. Manouchehrinia, A., F. Zhu, D. Piani-Meier, M. Lange, D.G. Silva, R. 
Carruthers, A. Glaser, E. Kingwell, H. Tremlett, and J. Hillert, Predicting 
risk of secondary progression in multiple sclerosis: A nomogram. Mult 
Scler. 2019; 25: 1102–1112.
79. Fambiatos, A., V. Jokubaitis, D. Horakova, E. Kubala Havrdova, M. 
Trojano, A. Prat, M. Girard, P. Duquette, A. Lugaresi, G. Izquierdo, F. 
Grand’Maison, P. Grammond, P. Sola, D. Ferraro, R. Alroughani, M. 
Terzi, R. Hupperts, C. Boz, J. Lechner-Scott, E. Pucci, R. Bergamaschi, 
V. Van Pesch, S. Ozakbas, F. Granella, R. Turkoglu, G. Iuliano, D. 
Spitaleri, P. McCombe, C. Solaro, M. Slee, R. Ampapa, A. Soysal, T. Pe-
tersen, J.L. Sanchez-Menoyo, F. Verheul, J. Prevost, Y. Sidhom, B. Van 
Wijmeersch, S. Vucic, E. Cristiano, M.L. Saladino, N. Deri, M. Barnett, 
J. Olascoaga, F. Moore, O. Skibina, O. Gray, Y. Fragoso, B. Yamout, C. 
Shaw, B. Singhal, N. Shuey, S. Hodgkinson, A. Altintas, T. Al-Harbi, T. 
Csepany, B. Taylor, J. Hughes, J.K. Jun, A. van der Walt, T. Spelman, H. 
Butzkueven, and T. Kalincik, Risk of secondary progressive multiple 
sclerosis: A longitudinal study. Mult Scler. 2020; 26: 79–90.
80. Kappos L, Fazekas F. 2015 Multiple Sclerosis Experts Summit. Neuro-
degener Dis Manag. 2015; 5(6 Suppl): 1–2, doi: 10.2217/nmt.15.54, 
indexed in Pubmed: 26611263.
81. Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease 
progression in secondary progressive multiple sclerosis (ASCEND): 
a phase 3, randomised, double-blind, placebo-controlled trial with an 
open-label extension. The Lancet Neurology. 2018; 17(5): 405–415, 
doi: 10.1016/s1474-4422(18)30069-3.
82. Montalban X, Hauser SL, Kappos L, et al. ORATORIO Clinical Investi-
gators. Ocrelizumab versus Placebo in Primary Progressive Multiple 
Sclerosis. N Engl J Med. 2017; 376(3): 209–220, doi: 10.1056/
NEJMoa1606468, indexed in Pubmed: 28002688.
83. Wolinsky JS, Narayana PA, O’Connor P, et al. PROMiSe Trial Study 
Group. Glatiramer acetate in primary progressive multiple sclero-
sis: results of a multinational, multicenter, double-blind, placebo-
-controlled trial. Ann Neurol. 2007; 61(1): 14–24, doi: 10.1002/
ana.21079, indexed in Pubmed: 17262850.
84. Hawker K, O’Connor P, Freedman MS, et al. OLYMPUS trial group. Ritu-
ximab in patients with primary progressive multiple sclerosis: results 
of a randomized double-blind placebo-controlled multicenter trial. Ann 
Neurol. 2009; 66(4): 460–471, doi: 10.1002/ana.21867, indexed in 
Pubmed: 19847908.
85. Lublin F, Miller D, Freedman M, et al. Oral fingolimod in primary 
progressive multiple sclerosis (INFORMS): a phase 3, randomised, 
double-blind, placebo-controlled trial. The Lancet. 2016; 387(10023): 
1075–1084, doi: 10.1016/s0140-6736(15)01314-8.
86. Wolinsky J. The PRO MiSe trial: baseline data review and progress 
report. Multiple Sclerosis Journal. 2017; 10(3_suppl): S65–S72, doi: 
10.1191/1352458504ms1034oa.
87. Hauser SL, Waubant E, Arnold DL, et al. HERMES Trial Group. B-cell 
depletion with rituximab in relapsing-remitting multiple sclerosis. N 
Engl J Med. 2008; 358(7): 676–688, doi: 10.1056/NEJMoa0706383, 
indexed in Pubmed: 18272891.
88. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between 
inflammation and neurodegeneration in multiple sclerosis brains. 
Brain. 2009; 132(Pt 5): 1175–1189, doi: 10.1093/brain/awp070, 
indexed in Pubmed: 19339255.
89. Abbatemarco JR, Fox RJ, Li H, et al. Vitamin D and MRI measures in 
progressive multiple sclerosis. Mult Scler Relat Disord. 2019; 35: 
276–282, doi: 10.1016/j.msard.2019.08.014, indexed in Pubmed: 
31445221.
90. Nathan J, Khedekar Kale D, Naik VD, et al. Dietary Therapy in Seconda-
ry Progressive Multiple Sclerosis: A Case Report. Cureus. 2019; 11(8): 
e5341, doi: 10.7759/cureus.5341, indexed in Pubmed: 31428547.
91. Chan D, Binks S, Nicholas J, et al. Effect of high-dose simvastatin on 
cognitive, neuropsychiatric, and health-related quality-of-life measures 
in secondary progressive multiple sclerosis: secondary analyses from 
the MS-STAT randomised, placebo-controlled trial. The Lancet Neuro-
logy. 2017; 16(8): 591–600, doi: 10.1016/s1474-4422(17)30113-8.
92. Goodman AD, Anadani N, Gerwitz L. Siponimod in the treatment of 
multiple sclerosis. Expert Opin Investig Drugs. 2019; 28(12): 1051–
1057, doi: 10.1080/13543784.2019.1676725, indexed in Pubmed: 
31603362.
93. Martinelli Boneschi F, Rovaris M, Capra R, et al. Mitoxantrone for 
multiple sclerosis. Cochrane Database Syst Rev. 2005(4): CD002127, 
doi: 10.1002/14651858.CD002127.pub2, indexed in Pubmed: 
16235298.
94. Chartier N, Epstein J, Soudant M, et al. Clinical follow-up of 411 pa-
tients with relapsing and progressive multiple sclerosis 10 years after 
discontinuing mitoxantrone treatment: a real-life cohort study. Eur J 
Neurol. 2018; 25(12): 1439–1445, doi: 10.1111/ene.13748, indexed 
in Pubmed: 29996003.
95. Wawrzyniak S, Rzepiński Ł. Is there a new place for mitoxantrone 
in the treatment of multiple sclerosis? Neurol Neurochir Pol. 2020; 
54(1): 54–61, doi: 10.5603/PJNNS.a2019.0069, indexed in Pubmed: 
31922582.
96. Sedel F, Bernard D, Mock DM, et al. Targeting demyelination and virtual 
hypoxia with high-dose biotin as a treatment for progressive multi-
ple sclerosis. Neuropharmacology. 2016; 110(Pt B): 644–653, doi: 
10.1016/j.neuropharm.2015.08.028, indexed in Pubmed: 26327679.
97. Tourbah A, Lebrun-Frenay C, Edan G, et al. MS-SPI study group. 
MD1003 (high-dose biotin) for the treatment of progressive multiple 
sclerosis: A randomised, double-blind, placebo-controlled study. Mult 
Scler. 2016; 22(13): 1719–1731, doi: 10.1177/1352458516667568, 
indexed in Pubmed: 27589059.
98. Spain R, Powers K, Murchison C, et al. Lipoic acid in secondary 
progressive MS: A randomized controlled pilot trial. Neurol Neu-
roimmunol Neuroinflamm. 2017; 4(5): e374, doi: 10.1212/
NXI.0000000000000374, indexed in Pubmed: 28680916.
398
Neurologia i Neurochirurgia Polska 2020, vol. 54, no. 5
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
99. La Mantia L, Vacchi L, Di Pietrantonj C, et al. Interferon beta for se-
condary progressive multiple sclerosis. Cochrane Database Syst Rev. 
2012; 1: CD005181, doi: 10.1002/14651858.CD005181.pub3, 
indexed in Pubmed: 22258960.
100. Placebo-controlled multicentre randomised trial of interferon beta-
-1b in treatment of secondary progressive multiple sclerosis. Europe-
an Study Group on interferon beta-1b in secondary progressive MS. 
Lancet. 1998; 352: 1491–7.
101. Kappos L, Weinshenker B, Pozzilli C, et al. European (EU-SPMS) 
Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial 
Steering Committee and Independent Advisory Board, North Ame-
rican (NA-SPMS) Interferon beta-1b in Secondary Progressive Mul-
tiple Sclerosis Trial Steering Committee and Independent Advisory 
Board. Interferon beta-1b in secondary progressive MS: a combined 
analysis of the two trials. Neurology. 2004; 63(10): 1779–1787, 
doi: 10.1212/01.wnl.0000145561.08973.4f, indexed in Pubmed: 
15557490.
102. Panitch H, Miller A, Paty D, et al. North American Study Group on 
Interferon beta-1b in Secondary Progressive MS. Interferon beta-
-1b in secondary progressive MS: results from a 3-year controlled 
study. Neurology. 2004; 63(10): 1788–1795, doi: 10.1212/01.
wnl.0000146958.77317.3e, indexed in Pubmed: 15557491.
103. Li DK, Zhao GJ, Paty DW, et al. University of British Columbia MS/
MRI Analysis Research Group. The SPECTRIMS Study Group. Rando-
mized controlled trial of interferon-beta-1a in secondary progressi-
ve MS: MRI results. Neurology. 2001; 56(11): 1505–1513, doi: 
10.1212/wnl.56.11.1505, indexed in Pubmed: 11402107.
104. Andersen O, Elovaara I, Färkkilä M, et al. Multicentre, randomised, 
double blind, placebo controlled, phase III study of weekly, low dose, 
subcutaneous interferon beta-1a in secondary progressive multiple 
sclerosis. J Neurol Neurosurg Psychiatry. 2004; 75(5): 706–710, 
doi: 10.1136/jnnp.2003.010090, indexed in Pubmed: 15090564.
105. Cohen JA, Cutter GR, Fischer JS, et al. IMPACT Investigators. Benefit 
of interferon beta-1a on MSFC progression in secondary progressive 
MS. Neurology. 2002; 59(5): 679–687, doi: 10.1212/wnl.59.5.679, 
indexed in Pubmed: 12221157.
106. Ravnborg M, Blinkenberg M, Sellebjerg F, et al. Responsiveness of the 
Multiple Sclerosis Impairment Scale in comparison with the Expan-
ded Disability Status Scale. Mult Scler. 2005; 11(1): 81–84, doi: 
10.1191/1352458505ms1120oa, indexed in Pubmed: 15732271.
107. Filippi M, Rossi P, Campi A, et al. Serial Contrast-Enhanced MR 
in Patients with Multiple Sclerosis and Varying Levels of Disabi-
lity. Journal of Neuro-Ophthalmology. 1999; 19(2): 115, doi: 
10.1097/00041327-199906000-00030.
108. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing 
and secondary progressive MS: part II: MRI results. MRI Analysis Cen-
ter of the University of Texas-Houston, Health Science Center, and the 
North American Linomide Investigators. Neurology. 2000; 54(9): 1734–
1741, doi: 10.1212/wnl.54.9.1734, indexed in Pubmed: 10802777.
109. Zhao Y, Petkau AJ, Traboulsee A, et al. Does MRI lesion activity re-
gress in secondary progressive multiple sclerosis? Mult Scler. 2010; 
16(4): 434–442, doi: 10.1177/1352458509359726, indexed in 
Pubmed: 20167592.
110. Amato MP, Ponziani G. Quantification of impairment in MS: discus-
sion of the scales in use. Mult Scler. 1999; 5(4): 216–219, doi: 
10.1177/135245859900500404, indexed in Pubmed: 10467378.
111. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and 
progression of irreversible disability in multiple sclerosis: an amnesic 
process. Brain. 2003; 126(Pt 4): 770–782, doi: 10.1093/brain/
awg081, indexed in Pubmed: 12615637.
112. Eriksson M, Andersen O, Runmarker B. Long-term follow up of 
patients with clinically isolated syndromes, relapsing-remitting 
and secondary progressive multiple sclerosis. Mult Scler. 2003; 
9(3): 260–274, doi: 10.1191/1352458503ms914oa, indexed in 
Pubmed: 12814173.
113. Tremlett H, Paty D, Devonshire V. Disability progression in multiple 
sclerosis is slower than previously reported. Neurology. 2006; 66(2): 
172–177, doi: 10.1212/01.wnl.0000194259.90286.fe, indexed in 
Pubmed: 16434648.
114. Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression 
in patients with multiple sclerosis who were treated with first gene-
ration immunomodulating drugs. Mult Scler. 2013; 19(6): 765–774, 
doi: 10.1177/1352458512463764, indexed in Pubmed: 23124789.
115. Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary pro-
gressive phase and long-term evolution of multiple sclerosis. J Neu-
rol Neurosurg Psychiatry. 2014; 85(1): 67–75, doi: 10.1136/jnnp-
2012-304333, indexed in Pubmed: 23486991.
116. Ribbons KA, McElduff P, Boz C, et al. Male Sex Is Independently 
Associated with Faster Disability Accumulation in Relapse-Onset 
MS but Not in Primary Progressive MS. PLoS One. 2015; 10(6): 
e0122686, doi: 10.1371/journal.pone.0122686, indexed in 
Pubmed: 26046348.
117. Brown JW, Coles A, Horakova D, et al. MSBase Study Group. Asso-
ciation of Initial Disease-Modifying Therapy With Later Conversion 
to Secondary Progressive Multiple Sclerosis. JAMA. 2019; 321(2): 
175–187, doi: 10.1001/jama.2018.20588, indexed in Pubmed: 
30644981.
118. Lizak, N., C.B. Malpas, S. Sharmin, E.K. Havrdova, D. Horakova, G. 
Izquierdo, S. Eichau, A. Lugaresi, P. Duquette, M. Girard, A. Prat, C. 
Larochelle, M. Trojano, F. Grand’Maison, P. Grammond, P. Sola, D. 
Ferraro, R. Hupperts, R. Bergamaschi, C. Boz, V. Van Pesch, D. Spita-
leri, M. Terzi, T. Kalincik, and M.S.S. Group, Association of Sustained 
Immunotherapy With Disability Outcomes in Patients With Active 
Secondary Progressive Multiple Sclerosis. 2020: JAMA.
119. Selmaj K, Li D, Hartung HP, et al. Siponimod for patients with 
relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-
-ranging, randomised, phase 2 study. The Lancet Neurology. 2013; 
12(8): 756–767, doi: 10.1016/s1474-4422(13)70102-9.
